Recent news on Remodulin

Start Making $67000 Today  -  May 17, 2007
Motley FoolThis biotech had just $30 million in revenue in 2002, nearly all of which came after the FDA approved its pulmonary arterial hypertension drug Remodulin in

Out of the Gate: United Therapeutics Up  -  May 8, 2007
Houston Chronicle,NEW YORK — Shares of biotechnology company United Therapeutics Corp. climbed Tuesday after a Citigroup analyst said its hypertension drug Remodulin has

United Therapeutics and Mochida Pharmaceutical Sign Remodulin ...  -  Mar 29, 2007
Drug Newswire (press release),..."We are delighted to work with Mochida as our exclusive partner to bring our lead product Remodulin to Japanese physicians and their patients."

United Therapeutics Enters Remodulin Distribution Agreement With ...  -  Mar 27, 2007
Trading Markets,Under the terms of the distribution agreement, Mochida Pharmaceutical will be responsible for obtaining marketing authorization for Remodulin with United

United Therapeutics inks deal with Japanese distribution partner  -  Mar 29, 2007
Bizjournals.com,The Silver Spring-based company's new partner, Mochida Pharmaceutical, will be responsible for obtaining marketing authorization for Remodulin in Japan with

Biotech Day In Review: Sanofi-Aventis Lands Cancer Vaccine For ...  -  Mar 29, 2007
Seeking Alpha,United Therapeutics (UTHR) out-licensed the Japanese rights for Remodulin Injection to Mochida Pharma. Remodulin is indicated for the treatment of pulmonary

United Therapeutics Inks Japan Deal  -  Mar 27, 2007
Houston Chronicle,Under terms of the agreement, Mochida, a Japanese pharmaceutical company with a cardiovascular focus, will obtain marketing authorization for Remodulin and

Market Report -- In Play (UTHR)  -  Mar 27, 2007
MSN MoneyUnited Thera and Mochida Pharmaceutical sign Remodulin distribution agreement for Japan Co and Mochida Pharmaceutical announce that the cos have signed an

Aradigm Revisited: CEO Adds Input to Analysis  -  Mar 29, 2007
Seeking Alpha,Although United Therapeutics has other inhaled forms of Remodulin under study, ARD-1500 has the advantage of less-frequent dosing.

United Therapeutics Announces Pulmonary Hypertension Opinion ...  -  Feb 27, 2007
Medical News Today (press release),..."We believe that if a patient is predisposed to sepsis, then subcutaneous Remodulin, which has never been associated with septicemia, is the safest

Study Raises Questions For United Therapeutics  -  Feb 26, 2007
Washington Post,United Therapeutics said Monday it will work closely with the pulmonary group to improve patient care using Remodulin, and that it planned to begin a

United Therapeutics Volume Heavy on Data  -  Feb 26, 2007
Forbes,Shares of United Therapeutics Corp. traded heavily Monday as the market reacted to scientific data affecting the drug maker's lead product Remodulin.

United Therapeutics Volume Heavy on Data  -  Feb 26, 2007
Houston Chronicle,Silver Spring, Md.-based United Therapeutics sells the prostacyclin treprostinil under the trade name Remodulin. The guidance came in reaction to a recent

Intravenous Treprostinil Linked to Higher Rate of Bloodstream ...  -  Mar 2, 2007
Medscape (subscription)...higher in patients receiving treprostinil (Remodulin, United Therapeutics) vs epoprostenol (Flolan, Gilead) for pulmonary arterial hypertension.

Intravenous treprostinil linked to increased rates of bloodstream ...  -  Mar 2, 2007
Therapeutics Daily (subscription) (press release),...of an increase in the number of blood stream infections associated with treprostinil (Remodulin), used to treat severe pulmonary arterial hypertension.

Aradigm Focuses on Inhaled Drugs  -  Mar 9, 2007
Seeking Alpha,Although United Therapeutics has other inhaled forms of Remodulin under study, ARD-1500 has the advantage of less-frequent dosing.

Premarket Movers: Brightpoint Rises  -  Feb 26, 2007
Forbes,The company's pulmonary hypertension treatment Remodulin is delivered to patients through a catheter. United Therapeutics plans to host a conference call on

Improved Long-Term Outcome With Remodulin Reported in European ...  -  Feb 1, 2007
PR Newswire (press release),The long-term outcome study published in the European Respiratory Journal demonstrated improved survival with Remodulin therapy when compared to predicted

United Therapeutics Reports 2006 Annual Financial Results  -  Feb 20, 2007
PR Newswire (press release),The increases in revenues and gross margins resulted primarily from expanded sales of both subcutaneous and intravenous delivered Remodulin.

Biotech drug firm sees 89% profit rise  -  Feb 20, 2007
Durham Herald Sun,SILVER SPRING, Md. -- Biotech drug developer United Therapeutics Corp. said Tuesday its fourth-quarter profit rose 89 percent as sales of its Remodulin

United Therapeutics Profit Soars  -  Feb 20, 2007
Forbes,Biotech drug developer United Therapeutics Corp. said Tuesday its fourth-quarter profit rose 89 percent as sales of its Remodulin product drove revenue.

United Therapeutics upgraded to "buy"  -  Feb 21, 2007
newratings.comIn a research note published yesterday, the analysts mention that sales of IV-Remodulin have grown faster than was earlier expected.

United Therapeutics reports sales up 40%  -  Feb 21, 2007
Baltimore Sun,That's $1 million more than United Therapeutics, which makes its money selling the drug Remodulin, a treatment for a blood vessel disorder in the lungs.

United Therapeutics shares rise on 4Q gains  -  Feb 20, 2007
Triangle Business Journal,Fourth quarter revenue also swelled in 2006, nearly topping $46 million on strong sales of Remodulin, a drug used to treat pulmonary arterial hypertension.

United Therapeutics initiated with "buy"  -  Feb 14, 2007
newratings.comThe analysts expect the market share for United Therapeutics' Remodulin to continue to expand moving ahead. The company is expected to continue to generate

United Therapeutics Reports 2006 Annual Financial Results  -  Feb 20, 2007
PR Newswire (press release),The increases in revenues resulted primarily from growth in sales of Remodulin(R). In 2006, we recognized a tax benefit of $34.1 million from a reduction of

Market Report -- In Play (UTHR)  -  Feb 1, 2007
MSN MoneyUnited Thera: Improved long-term outcome with Remodulin reported in European Respiratory Journal Co announces the publication of two important studies:

Analyst initiations 2-13-07: WebMD, ConAgra Foods initiated today  -  Feb 13, 2007
Blogging Stocks...higher incidence of serious Gram negative infections resulting in a Dear Doctor letter being sent to all IV-Remodulin prescribers in September 2006.

Market Report -- Short Stories (UTHR)  -  Feb 13, 2007
MSN Money...flagship pulmonary arterial hypertension product, infusible Remodulin, and successfully develop and market inhaled and oral formulations of the drug.

(PRN) - M/I Homes Reports Fourth Quarter and Year-End Results ... [+]  -  Feb 1, 2007
Bolsamania.com,...(PRN) - Improved Long-Term Outcome With Remodulin Reported in European Respiratory Journal and Rapid Transition to Remodulin Reported in Journal of

NewsWatch: Revenues, profits up at United Therapeutics  -  Feb 22, 2007
Business Gazette,The jump was due primarily to sales of the company’s lead product, Remodulin, officials said. Net income for the year grew 14 percent to $74 million.

Specialty Infusion Brings New Challenges, Solutions to Payers  -  Feb 12, 2007
Atlantic Information Services, Inc.,...under which drugs such as Remicade (infliximab), Novantrone (mitoxantrone), Flolan (epoprostenol sodium) and Remodulin (treprostinil sodium) fall.

Drugs from Gilead/GlaxoSmithKline and Encysive Will Challenge ...  -  Dec 5, 2006
Earthtimes.orgAdditionally, United Therapeutics' inhaled and oral versions of Remodulin, which are currently in clinical trials, have shown significant promise with few ...

United Therapeutics 3Q Profit Slides  Oct 31, 2006
Analysts expected revenue of $37.8 million. The company attributed its top-line growth to higher sales of its high-blood pressure drug Remodulin. ... -Houston Chronicle, Treprostinil Treatment Appears to Improve Health of Pulmonary ...  Oct 26, 2006
SALT LAKE CITY, UT -- October 26, 2006 -- Patients can handle safely be treated for up to 1 year with subcutaneous treprostinil (Remodulin) for pulmonary ... -DG News SI International's Profit Jumps 17 Percent  Oct 31, 2006
...excluding the expenses. Revenue jumped 22 percent, to $40.4 million, due to higher sales of its high-blood-pressure drug Remodulin. -Washington Post, United Therapeutics Reports Third Quarter 2006 Financial Results  Oct 31, 2006
...quarter of 2005. The increases in revenues and gross margins resulted primarily from growth in sales of Remodulin. Net income was ... -Earthtimes.org New Drug Fights Common Disease Among Premenopausal Women  Oct 9, 2006
Eventually, they all die. In 2001, Kosky's life was extended with remodulin, a new drug infused 24 hours a day through a pump in her abdomen. ... -Pittsburgh Channel.com, Good Buy for Biogen Idec  Sep 14, 2006
...trial), it's way too soon to compare Biogen's new PAH drug with Thelin, Myogen's (Nasdaq: MYOG) Ambrisentan, or United Therapeutics' (Nasdaq: UTHR) Remodulin. ... -Motley Fool

Biogen Idec Licenses PAH Drug From MondoBiotech  Sep 14, 2006
The product is an oral formulation of treprostinil, the active ingredient in UTC's Remodulin, approved for subcutaneous and intravenous treatment of PAH. ... -BioWorld Online

Drugs from Gilead/GlaxoSmithKline and Encysive Will Challenge ...  -  12 Dec 2006
Drug Newswire (press release),Additionally, United Therapeutics' inhaled and oral versions of Remodulin, which are currently in clinical trials, have shown significant promise with few

Actelion Adding PAH Power With $420M CoTherix Buyout  -  12 Dec 2006
BioWorld Online,..."The stock has not really outperformed [the market] simply because of competitive concerns over inhaled remodulin," Jaikaria said.

United Therapeutics 3Q Falls 37 Percent  Aug 1, 2006
Product sales rose 35 percent to $38.8 million, helped by higher sales of high blood pressure drug Remodulin. Expenses rose 52 percent to $28.7 million. ... -Houston Chronicle

United Therapeutics 3Q Net Falls  Aug 1, 2006
Analysts expected $34 million in revenue. Product sales rose 35 percent to $38.8 million, helped by higher sales of high blood pressure drug Remodulin. ... -Houston Chronicle

Biotech's shares decline 12 percent  Aug 2, 2006
They include customer stockpiling of its lead drug Remodulin, which treats a blood vessel disorder in the lungs, as well as a rise in the number of ... -Baltimore Sun

Investors Whipsaw Drug Firm's Stock Price  Aug 2, 2006
United Therapeutics sells Remodulin, a treatment for pulmonary arterial hypertension, a rare condition of dangerously high blood pressure in arteries between ... -Washington Post

United Therapeutics Q2 Earnings Falls; Misses Estimate - Update  Aug 1, 2006
...previous year quarter. The increase in revenues and gross margins was due to the growth in sales of Remodulin. Research and development ... -Trading Markets

United Therapeutics Reports Second Quarter 2006 Financial Results  Aug 1, 2006
...quarter of 2005. The increases in revenues and gross margins resulted primarily from growth in sales of Remodulin. Net income was ... -PR Newswire

United Therapeutics opens $32M lab in Silver Spring  Jun 29, 2006
The company licensed the drug Remodulin for the condition and commercialized it in an injected form. United is also working on inhaled ... -Business Gazette

United Therapeutics subsidiary finishes enrollment for cancer drug ...  Jun 21, 2006
United Therapeutics has built a roughly 50,000-square-foot lab near its headquarters that will produce materials used in both Remodulin, the company's lead drug ... -Washington Business Journal



Drug firm United Therapeutics to make Durham's RTP its new home  May 9, 2006
Chamber of Commerce. The plant will produce a tablet form of the firm's Remodulin therapy, which is a hypertension treatment. The drug ... - Durham Herald Sun

United Therapeutics moves on to ovarian cancer drug, new labs  Apr 27, 2006
United Therapeutics’ fortunes have been fueled by sales of Remodulin, which treats pulmonary arterial hypertension and which accounted for more than 90 ... - Business Gazette

United Therapeutics Reports First Quarter 2006 Financial Results  May 2, 2006
...quarter of 2005. The increases in revenues and gross margins resulted primarily from growth in sales of Remodulin. Net income was ... - PR Newswire

Accounting changes cut United Therapeutics profits  May 2, 2006
The company, whose drug Remodulin treats a rare form of lung disease, nearly doubled its research and development spending to $14.7 million as it works to ... - Washington Business Journal





FDA Approves United Therapeutics' Expanded Label Indication For ...  Mar 21, 2006
...(UTHR | charts | news | Powerrating) announced that its expanded label indication for Remodulin Injection has been approved by the United States Food and Drug ... - Trading Markets

United Therapeutics' Remodulin study OK'd  Mar 21, 2006
SILVER SPRING, Md., March 21 (UPI) -- United Therapeutics said Monday it has been OK'd on a study needed for accelerated approval of hypertension drug Remodulin ... - United Press International

FDA approves United Therapeutics' Remodulin label expansion  Mar 23, 2006
The FDA has approved United Therapeutics' supplemental new drug application for its pulmonary arterial hypertension drug Remodulin injection, granting the ... - Pharmaceutical Business Review

PAH: market ripe for expansion as big pharma interest increases  Mar 27, 2006
This interest was sparked by the launch of three new therapies and formulations in the US - United Therapeutics' IV Remodulin (treprostinil), CoTherix ... - Pharmaceutical Business Review

FDA Approves Expanded Label Indication and Satisfaction of Subpart ...  Mar 21, 2006
...today that the United States Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Remodulin(R) (treprostinil sodium ... - DG News

United Therapeutics Announces FDA OK  Mar 21, 2006
...that the Food and Drug Administration approved a supplemental new drug application allowing the company to sell its high blood pressure drug Remodulin as a ... - Houston Chronicle

North Carolina, Maryland vie for drug-making plant  Mar 27, 2006
One of the experimental drugs in the development pipeline is a pill version of Remodulin, an injectable treatment for pulmonary arterial hypertension that ... - TMCnet

United Therapeutics Says FDA Approved Supplemental New Drug ...  Mar 21, 2006
...charts | news | Powerrating) said on Tuesday that the US Food and Drug Administration has approved a supplemental New Drug Application for Remodulin Injection. ... - Trading Markets

Myogen helped by Thelin delay?  Mar 28, 2006
In addition to Actelion, the big players in this market are Pfizer`s Revatio, United Therapeutics` Remodulin, GlaxoSmithKline`s Flolan and CoTherix`s Ventavis. ... - Monsters and Critics.com

Drug Plant Lured By Incentives  Mar 28, 2006
The drug, an oral version of its lead product, Remodulin, used to treat high blood pressure in vessels between the heart and lungs, is winding its way through ... - International News Service

NewsWatch: IBM wins contract for Medicare IT  Mar 23, 2006
The Food and Drug Administration has approved a supplemental new drug application for the Remodulin injection developed by United Therapeutics Corp. ... - Business Gazette

Encysive Shares Tumble On FDA Thelin Approvable Letter  Mar 27, 2006
Other therapies for the condition include the prostacyclins Remodulin (treprostinil sodium, from United Therapeutics Corp.) and the inhaled Ventavis (iloprost ... - BioWorld Online (subscription)

Durham Tries To Lure $54 Million Drug Plant From Maryland  Mar 24, 2006
Earlier this month, United Therapeutics received FDA approval to sell its high blood pressure drug Remodulin as a supplemental drug for patients. ... - TechJournal South



United Therapeutics Reports 2005 Annual Financial Results  Feb 21, 2006
The increases in revenues and gross margins resulted primarily from expanded sales of Remodulin(R). Inventories held by United States distributors at the end ... - MSN Money

Revenue Up, but Below Target at Silver Spring-Based United ...  Feb 22, 2006
...yesterday, Chairman and CEO Martine A. Rothblatt attributed the growth to the company's continued efforts to work hypertension treatment Remodulin, its lead ... - International News Service,

Tax break pushes profits up at United Therapeutics  Feb 21, 2006
However, revenue at the Silver Spring-based maker of the hypertension drug Remodulin came in well below what Wall Street had projected. ... - Washington Business Journal,

US Stock-Index Futures Advance; Home Depot Climbs on Earnings  Feb 21, 2006
The maker of the Remodulin lung drug said fiscal second-quarter revenue was $29.6 million, less than the $35.6 million estimate of Punk Ziegel & Co. ... - Bloomberg

Israeli Ministry of Health Approves Intravenous Dosing of ...  Jan 10, 2006
Nasdaq: UTHR) announced today that the Drug Registration Department of the Israeli Ministry of Health has expanded the label of Remodulin(R) (treprostinil ... - PR Newswire

International Approvals: Tasmar, Amplimexon, IV Remodulin  Jan 17, 2006
...the Drug Registration Department of Israel's Ministry of Health approved a new route of administration for treprostinil sodium injection (Remodulin, made by ... - Medscape (subscription)

Biotech halts production of dietary supplements  Jan 26, 2006
The firm's lead marketed product, Remodulin, is for the treatment of pulmonary arterial hypertension, a disease caused by high blood pressure in the pulmonary ... - Washington Business Journal

Confessions of a Trader: Going Back to the Well  Jan 26, 2006
...diseases. The company's primary product, Remodulin is an injection for the treatment of pulmonary arterial hypertension (PAH). In ... - Schaeffers Research

Biotech halts production of dietary supplements  Jan 26, 2006
The firm's lead marketed product, Remodulin, treats pulmonary arterial hypertension, a disease caused by high blood pressure in the pulmonary artery that takes ... - Baltimore Business Journal

Zacks.com announces that Jim Collins highlights the following ...  Jan 24, 2006
United Therapeutics (Nasdaq:UTHR) announced last week that the Israeli Ministry of Health has expanded the label of Remodulin Injection to include intravenous ... - Business Wire

(PRN) - Unifi Second Quarter Earnings Conference Call ... [+]  Jan 10, 2006
...[+]. (PRN) - Israeli Ministry of Health Approves Intravenous Dosing of Remodulin(R) to Treat Pulmonary Arterial Hypertension ... [+. ... - Bolsamania.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional